File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Six-compound combo remedy ameliorates corticosterone-induced depressive behaviors in mice via targeting 5-hydroxytryptamine receptor 1A signaling

TitleSix-compound combo remedy ameliorates corticosterone-induced depressive behaviors in mice via targeting 5-hydroxytryptamine receptor 1A signaling
Authors
Issue Date31-Jul-2024
PublisherOxford University Press
Citation
Journal of Leukocyte Biology, 2024, p. 1-13 How to Cite?
Abstract

Dysregulation of brain innate immunity involving microglia is implicated in the pathology of neurological disorders including depression. Depression is a prominent medical challenge to global public health systems. Synthetic antidepressant drugs are limited by severe side effects. The present study aimed to identify the active compounds from the well-documented herbal medicine formula Banxia-Houpo decoction (BHD) and discover the underlying mechanisms for tuning microglia. We initially employed Liquid chromatography–mass spectrometry (LC-MS) profiling and network pharmacology analysis to predict the active compound–target interaction networks. We subsequently validated the potential active compounds and targets in a mouse model of corticosterone (CORT)-induced depression and postsynaptic microglia BV2 cells. As a result, 64 compounds were identified in the ethanolic Banxia-Houpo decoction extract and predicted to target 25 depression-related genes. Interestingly, the serotonergic synapse pathway received the highest enrichment score while 5-hydroxytryptamine receptor 1A (HTR1A) was targeted by 6 compounds (i.e. baicalein, luteolin, N-nornuciferine, roemerine, scutellarin, and 6-shogaol). In parallel assays, a six-compound combo (SCC) and Banxia-Houpo decoction markedly ameliorated the depressive-like behaviors in corticosterone-lesioned mice and well-protected highly differentiated (HD) PC12 cells against corticosterone challenge. Moreover, six-compound combo and Banxia-Houpo decoction effectively induced hydroxytryptamine receptor 1A expression in mice and postsynaptic microglia BV2 cells. Hydroxytryptamine receptor 1A antagonist WAY-100635 at 1 mg/kg/d via intraperitoneal injection attenuated the effects of six-compound combo and Banxia-Houpo decoction on the depressive behaviors in mice. These results suggest that six-compound combo might be a potential remedy against depression and other neurological disorders via targeting hydroxytryptamine receptor 1A in microglia.


Persistent Identifierhttp://hdl.handle.net/10722/347704
ISSN
2023 Impact Factor: 3.6
2023 SCImago Journal Rankings: 1.521

 

DC FieldValueLanguage
dc.contributor.authorSun, Yilu-
dc.contributor.authorChen, Qilei-
dc.contributor.authorCui, Wei-
dc.contributor.authorChen, Hubiao-
dc.contributor.authorZhao, Jia-
dc.contributor.authorRong, Jianhui-
dc.date.accessioned2024-09-27T00:30:25Z-
dc.date.available2024-09-27T00:30:25Z-
dc.date.issued2024-07-31-
dc.identifier.citationJournal of Leukocyte Biology, 2024, p. 1-13-
dc.identifier.issn0741-5400-
dc.identifier.urihttp://hdl.handle.net/10722/347704-
dc.description.abstract<p>Dysregulation of brain innate immunity involving microglia is implicated in the pathology of neurological disorders including depression. Depression is a prominent medical challenge to global public health systems. Synthetic antidepressant drugs are limited by severe side effects. The present study aimed to identify the active compounds from the well-documented herbal medicine formula Banxia-Houpo decoction (BHD) and discover the underlying mechanisms for tuning microglia. We initially employed Liquid chromatography–mass spectrometry (LC-MS) profiling and network pharmacology analysis to predict the active compound–target interaction networks. We subsequently validated the potential active compounds and targets in a mouse model of corticosterone (CORT)-induced depression and postsynaptic microglia BV2 cells. As a result, 64 compounds were identified in the ethanolic Banxia-Houpo decoction extract and predicted to target 25 depression-related genes. Interestingly, the serotonergic synapse pathway received the highest enrichment score while 5-hydroxytryptamine receptor 1A (HTR1A) was targeted by 6 compounds (i.e. baicalein, luteolin, N-nornuciferine, roemerine, scutellarin, and 6-shogaol). In parallel assays, a six-compound combo (SCC) and Banxia-Houpo decoction markedly ameliorated the depressive-like behaviors in corticosterone-lesioned mice and well-protected highly differentiated (HD) PC12 cells against corticosterone challenge. Moreover, six-compound combo and Banxia-Houpo decoction effectively induced hydroxytryptamine receptor 1A expression in mice and postsynaptic microglia BV2 cells. Hydroxytryptamine receptor 1A antagonist WAY-100635 at 1 mg/kg/d via intraperitoneal injection attenuated the effects of six-compound combo and Banxia-Houpo decoction on the depressive behaviors in mice. These results suggest that six-compound combo might be a potential remedy against depression and other neurological disorders via targeting hydroxytryptamine receptor 1A in microglia.<br></p>-
dc.languageeng-
dc.publisherOxford University Press-
dc.relation.ispartofJournal of Leukocyte Biology-
dc.titleSix-compound combo remedy ameliorates corticosterone-induced depressive behaviors in mice via targeting 5-hydroxytryptamine receptor 1A signaling-
dc.typeArticle-
dc.identifier.doi10.1093/jleuko/qiae167-
dc.identifier.spage1-
dc.identifier.epage13-
dc.identifier.eissn1938-3673-
dc.identifier.issnl0741-5400-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats